The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients

Bone Marrow Transplantation

Volumn 48, Issue 1, 2013, Pages 19-25

  Le Gall, J B ^a   Milone, M C ^b   Waxman, I M ^c   Shaw, L M ^b   Harrison, L ^d   Duffy, D ^d   Van De Ven, C ^d   Militano, O ^a   Geyer, M B ^e   Morris, E ^d   Bhatia, M ^a   Satwani, P ^a   George, D ^a   Garvin, J H ^a   Bradley, M B ^c   Schwartz, J ^f   Baxter Lowe, L A ^g   Cairo, M S ^d,h  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f Department of Medicine   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

Allogeneic stem cell transplantation; Children; Intravenous busulfan; Pediatrics; Pharmacokinetics

Indexed keywords

BUSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; VEIN OCCLUSION;

ADOLESCENT; AGE FACTORS; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HALF-LIFE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MYELOABLATIVE AGONISTS; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84872149353     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.105     Document Type: Article

References (29)

1. Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 523-536.
2. Hoy SM, Lyseng-Williamson KA. Intravenous busulfan: in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation. Paediatr Drugs 2007; 9: 271-278. (Pubitemid 47295847)
3. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225-230. (Pubitemid 26057312)
4. Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990; 50: 6203-6207. (Pubitemid 20323675)
5. Booth BP, Rahman A, Dagher R, Griebel D, Lennon S, Fuller D et al. Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. J Clin Pharmacol 2007; 47: 101-111. (Pubitemid 44974004)
6. Dalle JH, Wall D, Theoret Y, Duval M, Shaw L, Larocque D et al. Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results. Bone Marrow Transplant 2003; 32: 647-651. (Pubitemid 37258619)
7. Michel G, Valteau-Couanet D, Gentet JC, Esperou H, Socie G, Mechinaud F et al. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. Pediatr Blood Cancer 2012; 58: 90-97.
8. Nguyen L, Fuller D, Lennon S, Leger F, Puozzo CIV. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant 2004; 33: 979-987. (Pubitemid 38744783)
9. Tran H, Petropoulos D, Worth L, Mullen CA, Madden T, Andersson B et al. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 805-812. (Pubitemid 39406769)
10. Wall DA, Chan KW, Nieder ML, Hayashi RJ, Yeager AM, Kadota R et al. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer 2010; 54: 291-298.
11. Mellgren K, Nilsson C, Fasth A, Abrahamsson J, Winiarski J, Ringden O et al. Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: a comparative study between the standard 4-dose and a 2-dose regimen. Bone Marrow Transplant 2008; 41: 621-625. (Pubitemid 351524000)
12. LeGall J, Milone M, Waxman I, Shaw L, Harrison L, Duffy D et al. IV Busulfan administered q12 vs q6hrs during conditioning of pediatric allogeneic stem cell transplant (AlloSCT) recipients have comparable pharmacokinetics and significant reduction in nursing/pharmacist costs. Biol Blood Marrow Transplant 2011; 17: S258.
13. Fernandez HF, Tran HT, Albrecht F, Lennon S, Caldera H, Goodman MS. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twicedaily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 486-492. (Pubitemid 35174822)
14. Geyer MB, Jacobson JS, Freedman J, George D, Moore V, van de Ven C et al. A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients. Br J Haematol 2011; 155: 218-234.
15. Korecka M, Shaw LM. Review of the newest HPLC methods with mass spectrometry detection for determination of immunosuppressive drugs in clinical practice. Ann Transplant 2009; 14: 61-72.
16. Lai WK, Pang CP, Law LK, Wong R, Li CK, Yuen PM. Routine analysis of plasma busulfan by gas chromatography-mass fragmentography. Clin Chem 1998; 44: 2506-2510. (Pubitemid 28565663)
17. Bhatia M, Militano O, Jin Z, Figurski M, Shaw L, Moore V et al. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2010; 16: 333-343.
18. Osunkwo I, Bessmertny O, Harrison L, Cheung YK, Van de Ven C, del Toro G et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant 2004; 10: 246-258. (Pubitemid 38456203)
19. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
20. Waxman IM, Militano O, Baldinger L, Roman E, Qualter E, Morris E et al. Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning. Pediatr Transplant 2009; 13: 464-474.
21. Roman E, Osunkwo I, Militano O, Cooney E, van de Ven C, Cairo MS. Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation. Pediatr Blood Cancer 2008; 50: 325-330.
22. Shereck EB, Cooney E, van de Ven C, Della-Lotta P, Cairo MS. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients. Pediatr Blood Cancer 2007; 49: 306-312. (Pubitemid 47236221)
23. Styczynski J, Tallamy B, Waxman I, van de Ven C, Milone MC, Shaw LM et al. A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents. Bone Marrow Transplant 2011; 46: 790-799.
24. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Venoocclusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267. (Pubitemid 23046384)
25. Zwaveling J, den Hartigh J, Lankester AC, Guchelaar HJ, Egeler RM, Bredius RG. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Anticancer Drugs 2006; 17: 1099-1105. (Pubitemid 44454789)
26. Kletzel M, Jacobsohn D, Duerst R. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reducedintensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 472-479. (Pubitemid 43380964)
27. Kim AH, Tse JC, Ikeda A, Moore TB. Evaluating pharmacokinetics and pharmacodynamics of intravenous busulfan in pediatric patients receiving bone marrow transplantation. Pediatr Transplant 2009; 13: 971-976.
28. Simon A, Fleischack G, Hasan C, Bode U, Engelhart S, Kramer MH. Surveillance for nosocomial and central line-related infections among pediatric hematologyoncology patients. Infect Control Hosp Epidemiol 2000; 21: 592-596.
29. Horwitz ME, Morris A, Gasparetto C, Sullivan K, Long G, Chute J et al. Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients. Biol Blood Marrow Transplant 2008; 14: 591-594. (Pubitemid 351494747)